Enjoy complimentary customisation on priority with our Enterprise License!
Technavio’s market research analyst estimates the immunodiagnostics market in China to grow at an impressive CAGR of around 18% by 2020. The introduction of stringent healthcare reforms, growing preference for local manufacture of diagnostic devices, and rapidly increasing competition are some of the significant factors that augment growth in this market during the forecast period.
The rising prevalence of infectious and chronic diseases in this region is the primary growth driver for this market. In China, urbanization has led to an increase in the prevalence of chronic diseases like cancer, diabetes, cardiovascular diseases, and tuberculosis. This high prevalence of chronic diseases is envisaged to bolster the need for immunodiagnostic tests, which in turn would result in market growth during the forecast period.
The immunodiagnostic market in the China is consolidated due to the presence of numerous small, medium, and large vendors. The vendors in this market compete on the basis of product differentiation, application differentiation, portfolio, and pricing to gain maximum market traction during the forecast period.
The top vendors in the market are
Other prominent vendors in the market include AccuBio Tech,Alere,Becton Dickinson,Beijing Kewei Clinical Diagnostics Reagents, Beijing Leadman Biochemistry,Bio-RadBioscience Diagnostic Technology,Biosino Biotechnology & Science, DIAsource, DiaSys Diagnostic Systems, Fosun Pharma, Getein Biotechnology, Hitachi, Immunodiagnostic System Holdings, Luminex, NewScen Coast Bio-Pharmaceutical, Ortho Clinical Diagnostics, Shanghai Kehua Bio-engineering, Sichuan Maccura Biotechnology, Tecan, and Thermofisher Scientific.
According to this global market research report, the chemiluminescence (CLIA) assay segment is anticipated to be the largest market segment during the forecast period. The ability of this assay to perform clinical applications at a rapid pace is a major factor that augments its adoption during the forecast period. Moreover, this assay’s ability to make sample detection sensitive and easy is envisaged to result in its profound market share of more than 66% by 2020.
Technavio market research analysts estimate the reagents segment to account for a market share of approximately 82% during the forecast period. The ability of reagents to diagnose minute quantities of biological agents like hormones, viruses, vitamins, or immunogenic substances in blood samples is anticipated to result in its high adoption during the predicted period.
Get lifetime access to our
Technavio Insights
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.